Adam Egan's Colleagues at Co-Diagnostics
Adam Egan's Contact Details
801-438-1036
Salt Lake City,Utah,United States
Co-Diagnostics
Adam Egan's Company Details
MISSION STATEMENTAt Co-Diagnostics, we are passionate about providing the most robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications, especially to those regions where pricing is paramount. Our proprietary molecular diagnostics technology is paving the way for innovation in disease detection and life sciences research through our enhanced detection of genetic material. Because we own our platform, we are able to accomplish this faster and more economically, allowing for wider margins while still positioning Co-Diagnostics to be the worldwide low-cost leader of molecular diagnostics services.Co-Diagnostics, Inc. is a molecular diagnostics company with unique, patented Polymerase Chain Reaction ("PCR") testing technology. A Utah corporation headquartered in Salt Lake City, Utah, we commercialize our innovative patented and patent-pending technology through sales, development and licensing, to quickly develop molecular diagnostics that are more cost-efficient and perform better than traditional technologies of the past.Our technology has broad molecular applications: multiplexing, single nucleotide polymorphism (SNP) and mutation detection, real-time or traditional PCR detection, genotyping, RNA expression, and Sanger or next generation sequencing. The range of applications opens doors for us to develop tests related to multiple disciplines: infectious disease, oncology, transfusion medicine, pharmacogenetics, therapeutics, liquid biopsy, agriculture, or veterinary medicine. Researchers are able to quantify and analyze rare alleles and mutations using our advanced platform that includes unique, accelerated, ultra-specific attributes. Leading companies are applying our technology in a wide range of disciplines that can increase the speed, lower the cost and enhance the accuracy of their next generation sequencing.